Soft drugs in anesthesia: remifentanil as prototype to modern anesthetic drug development.

Article Details

Citation
Copy to clipboard

Birgenheier NM, Stuart AR, Egan TD

Soft drugs in anesthesia: remifentanil as prototype to modern anesthetic drug development.

Curr Opin Anaesthesiol. 2020 Jun 8. doi: 10.1097/ACO.0000000000000879.

PubMed ID
32530892 [ View in PubMed
]
Abstract

PURPOSE OF REVIEW: The unique demands of modern anesthesia practice require that medications be effective, well tolerated, and efficient. These attributes are increasingly achieved with the soft drug approach, wherein novel active compounds are specifically designed to be susceptible to rapid biotransformation to inactive metabolites. The present review summarizes the historical background and recent trends in soft drug development in anesthesiology. RECENT FINDINGS: Soft drug development programs for propranadid, etomidate, and benzodiazepine analogues have been undertaken in recent years. Although all three drugs advanced into human trials, neuro-excitatory adverse effects hampered the propranadid and etomidate analogue projects. Remimazolam, the soft benzodiazepine analogue, is at an advanced stage of development, having already received regulatory approval in several countries. SUMMARY: With succinylcholine as the historical forerunner and remifentanil as the modern prototype, the soft drug paradigm continues to hold promise for the future of anesthesia drug development.

DrugBank Data that Cites this Article

Drugs